ArticleActa dermato-venereologica2026
Hidradenitis Suppurativa Changes Major Life Decisions of Affected Patients: A Cross-sectional Study.
Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with substantial physical and psychosocial burden. Its long-term impact on major life-changing decisions (MLCD) remains poorly investigated. This cross-sectional study included 123 adult HS patients assessed using the validated Major Life-Changing Decision Profile (MLCDP). Disease severity was evaluated with Hurley staging and IHS4. Quality of life (DLQI, HiSQOL), disease acceptance (AIS), and psychiatric symptoms (PHQ-9, GAD-7) were also assessed. Overall, 87.887.8% of patients reported at least one affected MLCD, with a mean of 6.2±65.2 decisions per patient. The mean MLCDP total score was 20.1±1720.91 points, without sex differences. The most frequently affected areas concerned lifestyle habits, physical activity, and intimate relationships. Patients with Hurley stage III demonstrated significantly higher MLCDP scores compared with stages I and II. MLCDP correlated with IHS4 (r=r0.218), pain intensity (r=r0.256), DLQI (r=r0.401), HiSQOL (r=r0.507), PHQ-9 (r=r0.354), and GAD-7 (r=r0.315) (all p<p0.05). A strong inverse correlation was observed with illness acceptance (r = -0.584, p<p0.001). HS substantially influences key life decisions, particularly in patients with advanced disease and reduced psychological adaptation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.